Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 7, Number 2—April 2001
THEME ISSUE
4th Decennial International Conference on Nosocomial and Healthcare-Associated Infections

Prevention is Primary

HIV Postexposure Prophylaxis in the 21st Century

David K. HendersonComments to Author 
Author affiliation: Warren G. Magnuson Clinical Center, Bethesda, Maryland, USA

Main Article

Table

Clinical trials assessing the efficacy of antiretroviral agents in preventing maternal-fetal transmission of HIV

Study (ref) Regimena Timingb Outcome
Connor (15) ZDV A+L+P 8.3% vs 25.5%
Shaffer (28) ZDV A+L 9.4% vs 18.9%
Wiktor (29) ZDV A+L 12.2% vs 21.7%
Dabis (30) ZDV A+L+P 18.0% vs 27.5%
Wade (31) ZDV A+L+P 6.1% vs 26.6%
ZDV L+P 10.0% vs 26.6%
ZDV P (<48 hr) 9.3% vs 26.6%
ZDV P (>72 hr) 18.4% vs 26.6%
Bulterys (22) ZDV A+L+P 8.2% vs 15.5%
ZDV L+P 8.6% vs 15.5%
ZDV P 8.1% vs 15.5%
Saba (23) ZDV+3TC A+L+P 52% reduction
ZDV+3TC L+P 40% reduction
ZDV+3TC L no reduction
Blanche (24) ZDV+3TC A+L+P 2.6%
ZDV A+L+P 6.5%
Guay (25) ZDV L+P 25.1%
NVP L+P 13.1%

aZDV = zidovudine (azidothymidine); 3TC = lamivudine; NVP = nevirapine
bA - Prenatal therapy (usually beginning at 36 weeks); L - Therapy during labor and delivery; P - Postpartum treatment of infant.

Main Article

TOP